Exscientia

At the AACR Special Conference in Cancer Research, Dave H., Chief Scientific Officer of Recursion, shared interim monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors. 🔹 The interim Phase 1 clinical data for REC-617 included: ▪️ Dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker modulation, suggesting substantial target engagement; ▪️ Confirmed partial response (PR) during monotherapy dose-escalation in a patient with platinum-resistant ovarian cancer, treated with 4 lines of prior therapy in an advanced setting, with durable response ongoing after more than 6 months of treatment; ▪️ In 4 additional patients, a best response of stable disease (SD) for up to 6 months of treatment. Dr. Hallett noted: “Cell cycle dysregulation and transcriptional 'addiction' are both hallmarks of many aggressive cancers. By inhibiting CDK7, we have the potential to target both mechanisms while fine tuning the therapeutic index.” "These initial findings for REC-617 represent an exciting step forward in the development of CDK7 inhibitors, with a favorable PK/PD profile and a durable confirmed partial response observed in dose escalation in a highly pre-treated patient population," said Najat Khan, PhD, Chief R&D Officer and Chief Commercial Officer. “Designed using our AI-powered OS platform, REC-617 reflects our focus on enhancing the therapeutic index to deliver more effective and safer treatment options for patients. We are eager to continue this momentum in dose escalation and to initiate the next phase of the program next year." Learn more: https://lnkd.in/eExy4gBz #techbio #recursion #ai #clinicaltrial #cancer

Recursion featured in Deloitte's 2024 North America Technology Fast 500 list! ▪️ The list, now in its 30th year, is an annual ranking of the fastest-growing North American companies in technology and life sciences. ▪️ The awardees are selected based on percentage fiscal year revenue growth from 2020 to 2023. We are ranked 116 -- with 1,025% revenue growth. 👉 Learn more: https://lnkd.in/ev8PTq8 👉 Follow Recursion: https://lnkd.in/gM4r28fd #fast500 #techbio

🎉 Announcing our deal close with Recursion on the big screen -- Nasdaq MarketSite in Times Square! 🎉 #RXRX #TechBio

Today's update call with Recursion is available here! #TechBio https://lnkd.in/eCkwtWjm

The future of TechBio has arrived. Today we announce that our business combination with Recursion is officially closed, and two world-class, clinical stage TechBio companies have become one Recursion. We’re entering a new stage, for our company and for the TechBio industry. This combination allows us to move with even greater speed, precision, and efficiency to leverage AI, automation, and scientific expertise in order to develop new treatments for patients in need. 🔹 Highlights: ▪ Pipeline: Our combined pipeline has 10 clinical and preclinical, and 10 advanced discovery programs across rare disease, infectious disease, and oncology -- an unprecedented scale achievable only through the speed and efficiency brought by our combined AI-enabled platforms. ▪ Partnerships: We have more than 10 partnered programs with some of the largest pharma companies in the world – including Sanofi, Roche and Genentech, Bayer, and Merck KGaA, Darmstadt, Germany – and have received approximately $450 million in upfront and milestone payments. These partnerships could yield over $20 billion in additional milestones before royalties. In our partnership with Sanofi, focused on creating best-in-class therapies in inflammation and oncology, milestones have been achieved for three programs already. In our oncology partnership with Bayer, we have 2 joint projects rapidly advancing to Lead Series nomination, and another 20+ multimodal data packages in development.  ▪ Platform: Recursion's 60+ petabytes of proprietary data, millions of automated wet lab experiments per week, and machine learning models delivering Maps of Biology have been further enhanced with our precision chemistry capabilities driven by AI and automation to design and test highly optimized potentially first-in-class molecules for high-interest targets. 🔹 How We’re Improving Pharma Averages: ▪ 3X Speed: Traditional pharma takes 30 months to develop a validated candidate; we’re doing it in as little as 10 months. ▪ 10X Efficiency: Traditional pharma produces 2,500 molecules before they find a compound for testing; we’re producing just 250 on average. ▪ Up to 80% Cost Reduction: Traditional pharma costs $25-$35 million to reach an investigational new drug (IND); we’re getting there for $5-$10 million. 👉Learn more: https://lnkd.in/e7K5_qrQ 👉Follow Recursion at: https://lnkd.in/gM4r28fd  #ai #techbio #combination #partners 

On Nov. 20, join the call! On Nov. 13, we announced that Exscientia and Recursion shareholders have approved the proposed business combination. On Wed., Nov. 20, 7:30am ET, 5:30am MT, 12:30pm GMT, we’re holding a special update call to discuss the next chapter after the planned close of our business combination. This is a pivotal moment for the TechBio industry – bringing together two industry-leading pipelines, significant therapeutic discovery partnerships with leading pharma companies, and automated, AI-enabled platforms in biology and chemistry. 🔹 The update call will be livestreamed on LinkedIn, or tune in on:  ▪ X: https://lnkd.in/gn52iH5F  ▪ YouTube: https://lnkd.in/gNx66QJK 👉 Submit your questions here either prior to – or during – the livestream: https://lnkd.in/evTuuskj 👉 Learn more: https://lnkd.in/ehZE4-F7 

Don’t miss Richard J. Law, our Chief Business Officer, presenting at the Automated Synthesis Forum next week! Rich will give an overview on the role of AI, automation and partnerships in drug discovery at Exscientia. Learn more about the event here: https://lnkd.in/e8aGrnHz     #AI #Automation #DrugDiscovery 

If you’re attending Bio-Europe 2024 today, make sure you catch Nikolaus Krall, Exscientia’s EVP of Precision Medicine on the AI panel.  Nikolaus will be discussing how AI algorithms are reshaping our landscape, accelerating the identification and development of novel therapeutics, in the session titled ‘I Have a Dream - AI for drug discovery’.  Find out more here https://lnkd.in/dnuNZ2D  #AI #AIDrugDiscovery

Happy Sustainability Day!  At Exscientia, we're committed to minimising our environmental impact and leading the way in sustainable innovation. Our state-of-the-art automation studio embodies this commitment and has been designed with this in mind: - Powered by 100% renewable electricity: We're harnessing the power of nature to fuel our research   - Smart LED lighting: Efficiently illuminating our workspaces while reducing energy consumption   - High-efficiency air source heat pumps: Optimising our energy use across all seasons  These measures not only reduce our carbon footprint, but also demonstrate our dedication to sustainable science. We're excited to continue evolving and innovating towards a greener future for drug discovery.

At Exscientia, our research is inspired by the millions of people and their loved ones affected by breast cancer.     Our scientists are dedicated to pushing the boundaries of innovation, including with our investigational CDK7 inhibitor, using AI to explore potential new therapies that could change the lives of people living with breast cancer. We believe that every breakthrough brings us closer to more personalised, effective treatments.     This October, in recognition of Breast Cancer Awareness Month, we stand with the people affected by breast cancer and reaffirm our commitment to transforming the future of cancer care.     #Exscientia #BreastCancerAwarenessMonth #InnovationInHealth #AIForGood #BreastCancerResearch